Graft failure is a serious complication of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) defined as either lack of initial engraftment of donor cells (primary graft failure) …

Prolonged thrombocytopenia after hematopoietic stem cell transplantation (HSCT) is a
strong risk factor for transplantation-related morbidity and mortality, and no standard …

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from
anticancer medications and represents an important limitation for the use of antithrombotic …

The proinflammatory cytokine interferon-γ (IFN-γ) has been implicated in human
hematopoietic stem and progenitor cell (HSPC) depletion in immune-mediated bone marrow …

Poor graft function (PGF) is a life-threatening complication after allogeneic hematopoietic
stem cell transplantation (allo-HSCT) characterized by multilineage cytopenia in the …

Thrombocytopenia is a common adverse effect of chemotherapy. The development of
chemotherapy-induced thrombocytopenia (CIT) is influenced by cancer type and therapy …

Persistent cytopenia due to poor graft function (PoGF) is a relatively common complication
which may affect up to 20% of patients undergoing allogeneic hematopoietic stem cell …

Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem
cell transplantation (allo-SCT). Romiplostim and eltrombopag are the currently available …

Refractory thrombocytopenia is a frequent and severe complication after haploidentical
allogeneic hematopoietic stem cell transplantation (haplo-HSCT) and lacks effective …

Thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-SCT) can
pose significant problems in management of patients. Eltrombopag is a small-molecule …